- Drug Coverage
- Hypertrophic Cardiomyopathy (HCM)
- Vaccines: 2023 Year in Review
- Eyecare
- Urothelial Carcinoma
- Women's Health
- Hemophilia
- Heart Failure
- Vaccines
- Neonatal Care
- NSCLC
- Type II Inflammation
- Substance Use Disorder
- Gene Therapy
- Lung Cancer
- Spinal Muscular Atrophy
- HIV
- Post-Acute Care
- Liver Disease
- Pulmonary Arterial Hypertension
- Safety & Recalls
- Biologics
- Asthma
- Atrial Fibrillation
- Type I Diabetes
- RSV
- COVID-19
- Cardiovascular Diseases
- Breast Cancer
- Prescription Digital Therapeutics
- Reproductive Health
- The Improving Patient Access Podcast
- Blood Cancer
- Ulcerative Colitis
- Respiratory Conditions
- Multiple Sclerosis
- Digital Health
- Population Health
- Sleep Disorders
- Biosimilars
- Plaque Psoriasis
- Leukemia and Lymphoma
- Oncology
- Pediatrics
- Urology
- Obstetrics-Gynecology & Women's Health
- Opioids
- Solid Tumors
- Autoimmune Diseases
- Dermatology
- Diabetes
- Mental Health
KanCare moves forward before Fed approves it
Despite the fact that the federal government has not approved requests to waive a number regulations that would thwart it, Kansas is moving ahead with its KanCare Medicaid overhaul
Despite the fact that the federal government has not approved requests to waive a number regulations that would thwart it, Kansas is moving ahead with its KanCare Medicaid overhaul.
According to the Associated Press (AP), Gov. Sam Brownback plans to turn Medicaid over to three private, managed-care companies starting Jan. 1 after awarding contracts this summer.
But because the federal government provides a majority of the funding for the state's $2.9 billion-a-year program, it must approve multiple waivers Kansas has requested. The state administration is confident the waivers will be approved because the federal government has approved them for other states. Kansas expects approval in August, but AP quotes a federal spokesman who says there is no formal timetable for making a decision.
Kansas submitted its requests a day before new rules for waiver applications took effect. The new rules require two public hearings, public notifications and a report on public comments before submitting an application.
Go back to the Managed Healthcare Executive eNews newsletter.
FDA Updates for Week of May 27: 2 Approvals including New Biosimilar
June 1st 2024The FDA has made two approvals this week: the first interchangeable biosimilar of Soliris and another indication for Breyanzi for mantel cell lymphoma. The agency has delay a decision on Dupixent in COPD and has set goal dates for zolbetuximab in gastric cancer and zanidatamab in bile duct cancer.
Read More
A Conversation With Veteran Healthcare Lobbyist Paul Kelly | DC Roundtable
May 23rd 2024A limited pharmacy benefit manager (PBM) reform bill may be used as a "pay for" to offset the costs of extending Medicare telehealth flexibilities, shares Kelly, of Capitol Advocacy & Government Affairs.
Listen
The Relationship Between Physical Activity, Temperature and Hot Flashes During Menopause
May 30th 2024According to a recent survey published in Menopause, the journal of The Menopause Society, sudden changes in physical activity, temperature and humidity may increase the chances of hot flashes.
Read More
